Compare TNYA & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNYA | OSUR |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 214.1M |
| IPO Year | 2021 | 2000 |
| Metric | TNYA | OSUR |
|---|---|---|
| Price | $0.79 | $3.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $5.33 | $3.00 |
| AVG Volume (30 Days) | ★ 2.8M | 400.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.96 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $167,064,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $2.08 |
| 52 Week High | $2.35 | $3.76 |
| Indicator | TNYA | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 58.88 |
| Support Level | $0.64 | $3.10 |
| Resistance Level | $0.82 | $3.25 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 87.27 | 85.38 |
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.